The purpose of this study is to see if a new diagnostic research agent named 89Zr-DFO-MSTP2109A can show prostate cancer tumors on a PET scan; as well as see how long 89Zr-DFO-MSTP2109A lasts in the blood when given in small amounts. DFO-MSTP2109A is an antibody that works against STEAP1 - found on the surface of prostate cancer cells. Attached to the DFO-MSTP2109A is a radioactive material called 89ZR, which allows it to be imaged by a PET scanner. The results of this study may help researchers know whether 89Zr-DFO-MSTP2109A can be used as a diagnostic agent for finding prostate cancer that have STEAP1 on its surface with a PET scanner. The reason why identifying STEAP1 on prostate cancer cells is that new therapies are being developed to target STEAP1 prostate cancer cells.

Start Date01 Jan 2013

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

[+1]

100 Clinical Results associated with 89Zr-DFO-MSTP2109A

100 Translational Medicine associated with 89Zr-DFO-MSTP2109A

100 Patents (Medical) associated with 89Zr-DFO-MSTP2109A

Literatures (Medical) associated with 89Zr-DFO-MSTP2109A

01 Nov 2019·Journal of Nuclear MedicineQ1 · MEDICINE

Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody

Q1 · MEDICINE

Article

Author: Carrasquillo, Jorge A ; Humm, John L ; Pandit-Taskar, Neeta ; Fine, Bernard M ; Larson, Steven M ; Williams, Simon P ; Danila, Daniel C ; Ruan, Shutian ; Scher, Howard I ; Gönen, Mithat ; Lyashchenko, Serge K ; O'Donoghue, Joseph A ; Ragupathi, Govind ; Fleming, Stephen E ; Cheal, Sarah M ; Fox, Josef J ; Morris, Michael J

Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a relatively newly identified target in prostate cancer. We evaluated the ability of PET/CT with ⁸⁹Zr-DFO-MSTP2109A, an antibody that recognizes STEAP1, to detect lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: Nineteen mCRPC patients were prospectively imaged using approximately 185 MBq/10 mg of ⁸⁹Zr-DFO-MSTP2109A. ⁸⁹Zr-DFO-MSTP2109A PET/CT images obtained 4-7 d after injection were compared with bone and CT scans. Uptake in lesions was measured. Fifteen patients were treated with an antibody-drug conjugate (ADC) based on MSTP2109A; ADC treatment-related data were correlated with tumor uptake by PET imaging. Bone or soft-tissue biopsy samples were evaluated. Results: No significant toxicity occurred. Excellent uptake was observed in bone and soft-tissue disease. Median SUV_max was 20.6 in bone and 16.8 in soft tissue. Sixteen of 17 lesions biopsied were positive on ⁸⁹Zr-DFO-MSTP2109A, and all sites were histologically positive (1 on repeat biopsy). Bayesian analysis resulted in a best estimate of 86% of histologically positive lesions being true-positive on imaging (95% confidence interval, 75%-100%). There was no correlation between SUV_max tumor uptake and STEAP1 immunohistochemistry, survival after ADC treatment, number of ADC treatment cycles, or change in prostate-specific antigen level. Conclusion:⁸⁹Zr-DFO-MSTP2109A is well tolerated and shows localization in mCRPC sites in bone and soft tissue. Given the high SUV in tumor and localization of a large number of lesions, this reagent warrants further exploration as a companion diagnostic in patients undergoing STEAP1-directed therapy.

100 Deals associated with 89Zr-DFO-MSTP2109A

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prostatic Cancer	Phase 2	United States	Memorial Sloan Kettering Cancer Center	01 Jan 2013
Prostatic Cancer	Phase 2	United States	Genentech, Inc.	01 Jan 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01774071 (CTgov)	Phase 1/2	Prostatic Cancer	19	89Zr- DFO-MSTP2109A (89Zr DFOMSTP2109A Tracer Group 1)	zfbvrlpjkt(vejziowxpz) = pvhftgqvgc oboeiaewjr (hbvlwqbvnv, swdegcixin - sjfusffvba) View more	-	02 Oct 2024
				89Zr DFO-MSTP2109A (89Zr-DFO-MSTP2109A Tracer Group 2)	byhvykiawr(zhljjpmosa) = uvtmndcztt rsifktgpnu (rownyrghgt, nqlcovcbnc - fkkzovtcwk) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

89Zr-DFO-MSTP2109A

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation